002907 华森制药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)4.3274.6822.0266.8427.499
总资产报酬率 ROA (%)3.7014.0721.7595.4095.255
投入资产回报率 ROIC (%)4.2394.6572.0176.2696.154

边际利润分析
销售毛利率 (%)58.22057.27454.97859.33552.735
营业利润率 (%)16.93512.1066.62613.86012.210
息税前利润/营业总收入 (%)13.32610.6644.91614.16112.441
净利润/营业总收入 (%)10.8519.9034.72812.53210.847

收益指标分析
经营活动净收益/利润总额(%)76.03580.25384.08191.69790.159
价值变动净收益/利润总额(%)20.1701.474-10.910-2.407-1.283
营业外收支净额/利润总额(%)-18.370-0.384-7.071-0.5440.104

偿债能力分析
流动比率 (X)4.6654.8644.7424.5284.320
速动比率 (X)4.1334.2033.9383.9853.704
资产负债率 (%)14.40013.43112.61313.72928.539
带息债务/全部投入资本 (%)0.265-2.047-2.368-2.32913.681
股东权益/带息债务 (%)36,477.904-4,851.382-4,206.132-4,275.219608.029
股东权益/负债合计 (%)587.056644.531692.802628.379250.398
利息保障倍数 (X)-13.595-7.638-3.86537.74157.040

营运能力分析
应收账款周转天数 (天)82.42879.963100.52587.21170.350
存货周转天数 (天)136.402158.660154.033136.536110.723